A considerable proportion of patients with Coronavirus Disease 2019 (COVID-19) presents with a hypercoagulable state which may increase the risk of thromboembolic complications [1]. The most typical coagulation abnormalities reported in patients with COVID-19 are markedly elevated D-dimer levels, modest reductions in platelet count, and a small prolongation of the prothrombin time [1]. In severe cases, these coagulation changes may progress to disseminated intravascular coagulation, which is associated with a high mortality [2].